cytochrome C oxidase Inhibitors
3 drugsAbout cytochrome C oxidase
Cytochrome C oxidase (COX) is a mitochondrial enzyme essential for cellular respiration. It catalyzes the final step in the electron transport chain, transferring electrons to oxygen to produce water and drive ATP synthesis.
COX is a potential drug target due to its critical role in cellular energy production. Currently, there is no genetic evidence directly linking COX to specific diseases.
Three FDA-approved drugs target COX: CYANOKIT, MULTRYS, and TRALEMENT. All three drugs are small molecules and are classified within the 'other' therapeutic area.
Top cytochrome C oxidase Drugs
Two companies, AM REGENT and BTG INTL, have approved drugs targeting cytochrome C oxidase.
Low market concentration suggests relatively low barriers to entry for new competitors.
cytochrome C oxidase Drug Modality Landscape
Modalities
Routes of Administration
cytochrome C oxidase is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or peptides represents a whitespace opportunity.
cytochrome C oxidase Clinical Trials 41 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on cytochrome C oxidase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 | 100% |
| Phase 2 | 14 | 9 | 3 | 2 | 75% |
| Phase 3 | 9 | 6 | 0 | 3 | 100% |
| Phase 4 | 14 | 11 | 2 | 1 | 85% |
Top Sponsors
By Modality
Top Conditions
cytochrome C oxidase Drug Approval Timeline (2006 - 2020)
The first drug targeting COX was approved in 2006, with the most recent approval in 2020.
The 15-year span suggests a slow but steady interest in COX as a drug target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 35 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on cytochrome C oxidase. A trial counts if an approved drug acting on cytochrome C oxidase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.